D-0097-2023 Class II

Recalled by Pfizer Inc. — New York, NY

FDA drug recall D-0097-2023 was initiated by Pfizer Inc. on Dec 29, 2022 and is designated Class II. Reason for recall: Lack of assurance of sterility: Bags have the potential to leak. Affected quantity: 62,088 bags.

Recall details

Product Type
Drugs
Report Date
Jan 11, 2023
Initiation Date
Dec 29, 2022
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
62,088 bags

Product description

Heparin Sodium 2,000, USP Units, per 1,000 mL (2 USP Units/mL) in 0.9% Sodium Chloride Injection, 1,000 mL bags, a) Case (NDC 0409-7620-59), b) Single Unit (NDC 0409-7620-49), Rx only, Distributed By Hospira, Inc., Lake Forest, IL 60045 USA,

Reason for recall

Lack of assurance of sterility: Bags have the potential to leak.

Distribution pattern

Nationwide in the USA.

Code information

Lot: 5935283, Exp. 12/01/2023

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0097-2023
openFDA file date
Nov 19, 2026
Loaded by RegDataLab
Nov 20, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Need the full FDA record for Pfizer Inc.? Ask Claude or ChatGPT with the RegDataLab connector and get every site's inspections, Form 483s, warning letters, recalls and import alerts, each with a link to the FDA source. The API key is free: no card.

Get a free API key

How the connector works

Source: openFDA record for D-0097-2023. Report a data issue: hello@regdatalab.com.